Growater

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Growater
Generic name
MINOXIDIL
Manufacturer
Guangdong Jiaoyu Biotechnology Co., Ltd
Product type
HUMAN OTC DRUG
SPL set ID
5d55f726-9bd7-c198-e063-6394a90ae3d7
SPL ID
5d55f54f-9d12-c01b-e063-6394a90aeb0a
Version
1
Effective date
2026-10-08
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:25
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

For external use only. Do not use if: • Your hair loss is sudden, patchy, or the cause is unknown. • You are under 18 years of age. • Your scalp is red, inflamed, infected, irritated, or painful. • You use other medications or treatments on the scalp. Ask a doctor before use if: • You have heart disease. When using this product: • Apply only to the scalp. • Avoid contact with eyes. • Unwanted facial hair growth may occur. • Changes in hair color or texture may occur. • It may take 2-4 months to see results. • Results vary by individual. Stop use and ask a doctor if: • Chest pain, rapid heartbeat, dizziness, or fainting occurs. • Sudden weight gain or swelling occurs. • Severe scalp irritation occurs. • No hair growth occurs after 4 months of use.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.